ALX Oncology (ALXO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 40/100 (MEDIUM), 15.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.76% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-17. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 4 | Current Updated within the last 14 days |
ClinicalTrials.gov Registry queried: Nov 16, 2026 · ingested Nov 16, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 17, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 17, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 17, 2026 |
| Publications | 10 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 16, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 40.5/100 (grade D):
- Clinical trials: signal score 0.42, weight used 68%, 28.5 points
- Dilution risk: signal score 0.40, weight used 22%, 8.8 points
- Short interest: signal score 0.30, weight used 8%, 2.5 points
- Publications: signal score 0.50, weight used 1%, 0.7 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- ALX Oncology's Two Clinical Readouts Offer Potential Upside, UBS Says
- ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- ALX Oncology to Present at Upcoming Investor Conferences
- ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
- ALX Oncology to Present at Upcoming Investor Conferences in September
- Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
- ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial. — Nat Med 2026 Sep 24 PMID 42786305
- Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study. — Haematologica 2025 Sep 1 PMID 40207726
- Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. — Nat Med 2022 Feb PMID 35027753
- Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. — Lancet Oncol 2021 Dec PMID 34793719
- Direct control of CAR T cells through small molecule-regulated antibodies. — Nat Commun 2021 Jan 29 PMID 33514714
10 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for ALX Oncology.
Full ALXO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.